ERBB2 and oligohydramnios: The ROR was significantly higher than 1 in anti-ERBB2 drug–exposed reports for oligohydramnios (ROR, 17.68 [95% CI, 12.26-25.52]; P < .001), fetal malformation NOS (ROR, 3.04 [95% CI, 1.29-7.14]; P = .02), congenital respiratory tract disorders (ROR, 9.98 [95% CI, 2.88-34.67]; P = .001), and neonatal kidney failure (ROR, 9.15 [95% CI, 4.62-18.12]; P < .001) (Figure 3).